Spyre Therapeutics, Inc. SYRE Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s accrued expenses and other liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported accrued expenses and other liabilities of $3.65M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s accrued expenses and other liabilities increased by 160.9% year-over-year, from -$6M to $3.65M.